MAPK3 and cardiac hypertrophy: Although ERK1/2 are thought to be the central mediators of cardiac hypertrophy and are regarded as potential therapeutic targets, however, the direct inhibition of ERK1/2 may also unexpectedly lead to exacerbated cardiomyocyte death and impaired heart function [86,87].